Get started
Work

Ph Ii Study of Bez235 in Patients with Advanced Pancreatic Neuroendocrine Tumors (Pnet) After Mtor Inhibitor Therapy Failure: Stage I Interim Results

Year: 2014
Type: article
Study design: Clinical Trial
DOI: 10.1093/annonc/mdu345.12
Authors: N. Fazio, R. Buzzoni, E. Baudin, L. Antonuzzo, R. Hubner, H. Lahner, W.W. De Herder, M. Raderer, A. Teule, J. Capdevila, S. Libutti, M. Kulke, M. Shah, D. Dey, S. Turri, P. Aimone, C. Verslype
Institutions: European Institute of Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Institut Gustave Roussy, Azienda Ospedaliero-Universitaria Careggi, The Christie Hospital, The Christie NHS Foundation Trust, University of Duisburg-Essen, Erasmus MC, University of Vienna, Medical University of Vienna, Institut Català d'Oncologia, Vall d'Hebron Hospital Universitari, Albert Einstein College of Medicine, Montefiore Medical Center, Dana-Farber Cancer Institute, The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, The Ohio State University, Novartis (India), Novartis (Switzerland), KU Leuven
Language: English
Subfield: Epidemiology
Field: Medicine
Open Access status: bronze
OpenAlex ID: W2337213691
FWCI: 0.674
Cites:
Cited by: 5
Related to: 10